Cartesian Therapeutics, Inc. (RNAC): Total Liabilities
$422.65M
As of 2025-12-31
$443.85M
As of 2026-06-30
+80.3%
3-year compound annual growth
+18.2%
5-year compound annual growth
+34.5%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $422.65M | -4.3% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $441.82M | -0.6% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $444.68M | +517.1% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $72.06M | -47.5% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $137.36M | -25.1% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $183.44M | +101.2% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $91.17M | +82.7% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $49.90M | +1.2% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $49.29M | +43.5% | 2019-03-15, Balance as of period end |
| 2016-12-31 | $34.34M | +57.3% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $21.84M | n/a | 2017-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $422.65M | -4.3% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $14.00M | +18.0% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $968.0K | +8.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $2.52M | -19.0% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $70.10M | +362.3% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $2.27M | -34.4% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $37.52M | +74.3% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $2.53M | +67.1% |
Compare RNAC, UPB, XBIO, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗